amorchem header logo close button Menu
arrow leftBack to news

Dr Joshua Dunaief MD, renowned AMD Clinician and Researcher, joins Mperia Therapeutics Inc. Clinical Advisory Board

Montreal – (BusinessWire) – March 18, 2019, Dr. Joshua Dunaief, PhD, MD, the Adele Niessen Professor of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, USA, joins the Clinical Advisory Board (CAB) of Mperia Therapeutics Inc.

“A front-line Age-Related Macular Degeneration (AMD) clinician for two decades, combined with a stellar research reputation around oxidative stress in the eye, means Dr Dunaief is the perfect final appointee to our CAB as we finalize our clinical Phase 1 and 2 plans,” stated CEO & President, Paul Chipperton.

“The addition of Dr. Dunaief further expands the ocular expertise now available to Mperia at a critical stage of the company’s development.” said Kevin McBride, Mperia board member, and Partner & CSO at AmorChem.  “He will play a key role in transforming Mperia from a preclinical stage company into one pursuing clinical studies on CD36, a potentially game-changing target for AMD and other inflammatory diseases.”

Dr. Dunaief, PhD, MD is the Adele Niessen Professor of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, USA. He has cared for patients with AMD since 2000, and concurrently his research activity focuses on developing new understanding and treatment in the field. His lab has published over 100 peer-reviewed articles related to AMD. He was given the Cogan Award by the Association for Research in Vision and Ophthalmology in 2006.

Both his research and clinical experience spans several of the most esteemed University Medical Schools in the US, receiving his BA magna cum laude in Biology from Harvard University, an MD/PhD from Columbia College of Physicians and Surgeons (1996), and completed his ophthalmology residency at the Wilmer Eye Institute, Johns Hopkins in 2000, before joining Scheie Eye Institute, University of Pennsylvania where he completed a medical retina fellowship in 2004.


Mperia Therapeutics is The CD36 Therapeutics Company focusing on macrophage-driven inflammation. The technology exploits CD36-targeting cyclic peptides and their capacity to impact the cell inflammasome and modify macrophages’ metabolic dysfunction, resulting in outstanding anti-inflammatory response. Mperia holds exclusive rights to several highly-efficacious CD36 receptor ligands to be used in dry AMD, atherosclerosis and NASH.

Contact Media:

Paul Chipperton, BSc, MBA
CEO & President – Mperia Therapeutics Inc.
T: +1-647-291-8545

Kevin McBride, PhD
Partner & CSO, AmorChem
T: +1-514-849-7696
E :